Logo image of MIST

MILESTONE PHARMACEUTICALS IN (MIST) Stock Fundamental Analysis

USA - NASDAQ:MIST - CA59935V1076 - Common Stock

2 USD
+0.03 (+1.52%)
Last: 9/26/2025, 8:12:32 PM
2.0093 USD
+0.01 (+0.47%)
After Hours: 9/26/2025, 8:12:32 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to MIST. MIST was compared to 196 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of MIST have multiple concerns. MIST has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year MIST has reported negative net income.
In the past year MIST has reported a negative cash flow from operations.
In the past 5 years MIST always reported negative net income.
MIST had a negative operating cash flow in each of the past 5 years.
MIST Yearly Net Income VS EBIT VS OCF VS FCFMIST Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

MIST has a worse Return On Assets (-117.11%) than 79.08% of its industry peers.
Industry RankSector Rank
ROA -117.11%
ROE N/A
ROIC N/A
ROA(3y)-70.9%
ROA(5y)-56.36%
ROE(3y)-253.25%
ROE(5y)-166.55%
ROIC(3y)N/A
ROIC(5y)N/A
MIST Yearly ROA, ROE, ROICMIST Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MIST so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MIST Yearly Profit, Operating, Gross MarginsMIST Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K

More info and screens

3

2. Health

2.1 Basic Checks

MIST does not have a ROIC to compare to the WACC, probably because it is not profitable.
MIST has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, MIST has more shares outstanding
MIST has a worse debt/assets ratio than last year.
MIST Yearly Shares OutstandingMIST Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
MIST Yearly Total Debt VS Total AssetsMIST Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

MIST has an Altman-Z score of -11.63. This is a bad value and indicates that MIST is not financially healthy and even has some risk of bankruptcy.
MIST has a Altman-Z score of -11.63. This is in the lower half of the industry: MIST underperforms 71.94% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -11.63
ROIC/WACCN/A
WACC9%
MIST Yearly LT Debt VS Equity VS FCFMIST Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 4.97 indicates that MIST has no problem at all paying its short term obligations.
With a decent Current ratio value of 4.97, MIST is doing good in the industry, outperforming 68.88% of the companies in the same industry.
MIST has a Quick Ratio of 4.97. This indicates that MIST is financially healthy and has no problem in meeting its short term obligations.
MIST has a better Quick ratio (4.97) than 69.39% of its industry peers.
Industry RankSector Rank
Current Ratio 4.97
Quick Ratio 4.97
MIST Yearly Current Assets VS Current LiabilitesMIST Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

1

3. Growth

3.1 Past

MIST shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.76%, which is quite good.
The Revenue for MIST has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)16.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-42.86%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, MIST will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.82% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-25.83%
EPS Next 2Y-23.48%
EPS Next 3Y-20.44%
EPS Next 5Y11.82%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MIST Yearly Revenue VS EstimatesMIST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
MIST Yearly EPS VS EstimatesMIST Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MIST. In the last year negative earnings were reported.
Also next year MIST is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MIST Price Earnings VS Forward Price EarningsMIST Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MIST Per share dataMIST EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.2 -0.4 -0.6 -0.8 -1

4.3 Compensation for Growth

MIST's earnings are expected to decrease with -20.44% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-23.48%
EPS Next 3Y-20.44%

More info and screens

0

5. Dividend

5.1 Amount

MIST does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MILESTONE PHARMACEUTICALS IN

NASDAQ:MIST (9/26/2025, 8:12:32 PM)

After market: 2.0093 +0.01 (+0.47%)

2

+0.03 (+1.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-12 2025-08-12/bmo
Earnings (Next)11-10 2025-11-10/bmo
Inst Owners20.29%
Inst Owner Change-6.6%
Ins Owners3.61%
Ins Owner Change5.01%
Market Cap169.98M
Analysts78
Price Target3.57 (78.5%)
Short Float %6.61%
Short Ratio3.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-37.37%
Min EPS beat(2)-64.28%
Max EPS beat(2)-10.47%
EPS beat(4)1
Avg EPS beat(4)-21.68%
Min EPS beat(4)-64.28%
Max EPS beat(4)15.96%
EPS beat(8)4
Avg EPS beat(8)-3.55%
EPS beat(12)8
Avg EPS beat(12)1.59%
EPS beat(16)10
Avg EPS beat(16)2.21%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5%
PT rev (3m)-30%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.5%
EPS NY rev (1m)0%
EPS NY rev (3m)14.14%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.85
EYN/A
EPS(NY)-1.05
Fwd EYN/A
FCF(TTM)-0.48
FCFYN/A
OCF(TTM)-0.48
OCFYN/A
SpS0
BVpS-0.21
TBVpS-0.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -117.11%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-70.9%
ROA(5y)-56.36%
ROE(3y)-253.25%
ROE(5y)-166.55%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 40.57%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.97
Quick Ratio 4.97
Altman-Z -11.63
F-Score3
WACC9%
ROIC/WACCN/A
Cap/Depr(3y)151.06%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-42.86%
EPS Next Y-25.83%
EPS Next 2Y-23.48%
EPS Next 3Y-20.44%
EPS Next 5Y11.82%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-11.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year50.27%
EBIT Next 3Y-12.79%
EBIT Next 5Y29.19%
FCF growth 1Y17.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y17.44%
OCF growth 3YN/A
OCF growth 5YN/A